In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation-Reference-Cited by-同舟云学术

In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation

Published:2020-03-06 Issue:4 Volume:39 Page:1491-1505
ISSN:0739-1102
Container-title:Journal of Biomolecular Structure and Dynamics
language:en
Short-container-title:Journal of Biomolecular Structure and Dynamics

Author:

Patel Harun M.¹,Ahmad Iqrar¹,Pawara Rahul¹,Shaikh Matin¹,Surana Sanjay¹

Affiliation:

1. Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India

Publisher

Informa UK Limited

Subject

Molecular Biology,General Medicine,Structural Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07391102.2020.1734092

Reference34 articles.

1. Caco‐2 Cells as a Model for Intestinal Absorption

2. BDDCS, the Rule of 5 and drugability

3. Computational prediction of formulation strategies for beyond-rule-of-5 compounds

4. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions

5. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular docking, QSAR, and simulation analyses of EGFR-targeting phytochemicals in non-small cell lung cancer;Journal of Molecular Structure;2025-02

2. Unveiling the antibacterial efficacy of thiazolo [3,2‐a] pyrimidine: Synthesis, molecular docking, and molecular dynamic simulation;Journal of Biochemical and Molecular Toxicology;2024-08-31

3. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

4. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

5. Auto QSAR-based Active learning docking for hit identification of potential inhibitors ofPlasmodium falciparumHsp90 as antimalarial agents;2024-05-18